Management of major bleeding and outcomes in patients treated with direct oral anticoagulants: results from the START Event registry
|
|
- Jared Malone
- 5 years ago
- Views:
Transcription
1 IM - ORIGINAL Management of major bleeding and outcomes in patients treated with direct oral anticoagulants: results from the START Event registry Sophie Testa 1 Walter Ageno 2 Emilia Antonucci 3 Rossella Morandini 1 Jan Beyer Westendorf 4 Maurizio Paciaroni 5 Marc Righini 6 Piera Sivera 7 Peter Verhamme 8 Vittorio Pengo 9 Daniela Poli 10 Gualtiero Palareti 3 Received: 8 January 2018 / Accepted: 7 May 2018 The Author(s) 2018 Abstract The management of major bleeding in patients treated with direct oral anticoagulants (DOACs) is still not well established. START-Events, a branch of the START registry (Survey on anticoagulated patients RegisTer) (NCT ), aims to describe the actual management of bleeding or recurrent thrombotic events in routine clinical practice. We here present the results of the management of bleeding patients. The START-Event registry is a prospective, observational, multicenter, international study. Baseline characteristics (demographic, clinical, risk factors) of patients, laboratory data at admission and during follow-up, site of bleeding, therapeutic strategies, and outcomes at the time of hospital discharge and after 6 months were recorded on a web-based case report form. Between January 2015 and December 2016, 117 patients with major bleeding events were enrolled. Non-valvular atrial fibrillation (NVAF) was the indication for treatment in 84% (62% males); 53 patients had intracranial bleeding (13 fatal), 42 had gastrointestinal bleeding (1 fatal), and 22 had bleeding in other sites. Therapeutic interventions for the management of bleeding were performed in 71% of patients. Therapeutic strategies with/ without surgery or invasive procedures included: fluid replacement or red blood cells transfusion, prothrombin complex concentrates (3 or 4 factors), antifibrinolytic drugs, and the administration of idarucizumab. Creatinine, blood cell count, and PT/aPTT were the most frequent tests requested, while specific DOAC measurements were performed in 23% of patients. Mortality during hospitalization was 11.9%, at 6-month follow-up 15.5%. Our data confirm a high heterogeneity in the management of bleeding complications in patients treated with DOACs. Keywords Bleeding Direct oral anticoagulant Idarucizumab Introduction The study was promoted through the SSC Control of Anticoagulation of the International Society of Thrombosis and Haemostasis. * Sophie Testa s.testa@asst cremona.it 1 Haemostasis and Thrombosis Center, Ospedale di Cremona, Viale Concordia 1, Cremona, Italy 2 3 Department of Medicine and Surgery, University of Insubria, Varese, Italy Arianna Anticoagulazione Foundation, Bologna, Italy 4 Dresden University Clinic, Dresden, Germany In the past few years, direct oral anticoagulants (DOACs) have been introduced in clinical practice for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NAVF), and for the prevention and treatment of venous thromboembolism (VTE) [1]. 5 Stroke Unit, Università di Perugia, Perugia, Italy 6 Division of Angiology and Hemostasis, Geneva University Hospital, Geneva, Switzerland 7 8 Ospedale Mauriziano Torino, Turin, Italy UZ Gasdthuisberg, Louvain, Belgium 9 Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Padua, Italy 10 Thrombosis Centre, AOU Careggi, Florence, Italy Vol.:( )
2 At present, available drugs include dabigatran, a selective anti-factor IIa molecule and three direct factor Xa inhibitors: apixaban, edoxaban, and rivaroxaban. In phase III clinical studies, all these agents have shown non-inferiority or superiority compared with vitamin K antagonists (VKA) in terms of efficacy and safety [2 6]. Due to their pharmacological characteristics (i.e., rapid onset of action, short half-life, predictable anticoagulant effect in standard conditions, low food/drug interactions without any important need for restrictions, metabolism, and elimination), the DOACs allow fixed dose administration, and do not require laboratory monitoring [7, 8]. However, the measurement of the activity of the DOACs provides clinically useful information in a number of special conditions such as in the case of bleeding or thromboembolic complications while on treatment to evaluate a correlation between events and over/under treatment, and to address specific treatment approaches [9 13]. Major bleeding during anticoagulant treatment remains a crucial issue, with estimated incidences ranging from 2 to 3% in clinical trials [6] to up to 4% in observational post-marketing studies [14]. Yet, the optimal management of bleeding complications on DOACs therapy is still poorly defined given that the limited evidence to support different therapeutic approaches. Reversal agents are still under investigation, and currently only idarucizumab [15], the specific antidote for dabigatran, is available in the market. Andexanet alfa, the reversal agent for direct and indirect factor Xa inhibitors, is still under investigation [16, 17], whereas more preliminary data are available for ciraparantag, a universal antidote [18]. Similarly, the efficacy and safety of the administration of procoagulant factors, which are suggested by international guidelines [8, 11] for patients on direct Factor Xa inhibitors, is uncertain [19]. START-SSC Events, a branch of the START registry (Survey on anticoagulated patients RegisTer) (NCT ) [20] promoted through the Scientific and Standardization Committee (SSC) Control of Anticoagulation of the International Society of Thrombosis and Haemostasis, aims to describe the actual management of bleeding or recurrent thrombotic events in patients treated with the DOACs in routine clinical practice. In this study, we describe the management of major bleeding with respect to therapeutic strategies (medical therapies, surgery, or interventional procedures), laboratory testing, and other supportive measures, and we describe the adherence to currently available guidelines and recommendations in clinical practice. Methods Patients START-SSC Events is a prospective, observational, multicenter, international registry that includes patients with acute complications during treatment with DOACs. The study was conducted in 15 centers among 7 different countries (Belgium, Brazil, Germany, Italy, Switzerland, USA, and Thailand). All participating centers are asked to report in the registry all available clinical and laboratory data collected in consecutive patients aged more than 18 years presenting with major bleeding or thromboembolic complications. In this article, we only report data on patients presenting with major bleeding events. The study protocol of START-SSC Event registry was approved by the local ethics committees, and was conducted in accordance with the Declaration of Helsinki. Written informed consent was collected according to local practice. Data collection Baseline characteristics (age, gender, type of DOAC, clinical indication), laboratory findings at admission and during follow-up, site of bleeding, diagnostic procedures, therapeutic strategies, and outcomes at the time of hospital discharge and after 6 months were recorded on a web-based case report form (CRF). Information was collected by the local investigators, and central monitoring of the quality of data was performed at the coordinating center. Investigators were contacted in case of missing values or discrepancies. The 6-month follow-up visits were performed at the participating clinics or by phone contact. Laboratory tests included: blood cell count, liver enzymes (AST, ALT), renal function (creatinine clearance calculated using the Cockcroft Gault formula), coagulation screening tests (PT and aptt), and specific DOAC measurements. DOACs levels, expressed as drug concentration equivalent (ng/ml), were measured with diluted thrombin time (dtt) or ecarin chromogenic assay (ECA) calibrated for dabigatran and specific anti-factor X activated (FXa) assays calibrated for apixaban, edoxaban, and rivaroxaban [12, 21, 22]. All tests were performed locally, and each investigator made decision on whether to perform laboratory or not. Major bleeding and outcomes In this study, we adopted the criteria of the International Society on Thrombosis and Haemostasis, which defines major bleeding as fatal bleeding or symptomatic bleeding in critical area or organ, or bleeding causing a fall of
3 hemoglobin level of 20 g/l (1.24 mmol/l or 2 g/dl) or more, or leading to transfusion of 2 units of whole blood or red cells [23]. Study outcomes during follow-up include mortality and disability. The Barthel index [24] was used to define disability, and dependence in activities of daily living was assessed by the local investigator at the time of hospital discharge and after 6 months. Disability [evaluated for intracranial hemorrhage (ICH) patients only] was defined by a score < 100 of Barthel index. Guidelines Routine strategies described in the study were compared with the recommendations of international guidelines. We referred to the guidelines published by European Heart Rhythm Association (EHRA) in 2016 [11]. In brief, the following procedures are recommended in case of major bleeding events: stop DOACs; provide patient stabilization (assessment of vital signs, fluid resuscitation, mechanical compression); identify the DOAC taken by the patient and the time of the last dose intake; check for blood cell count, renal and liver function, screening coagulation tests, or specific DOAC measurements; add symptomatic treatment (fluid replacement, blood transfusion); treat bleeding cause if possible (e.g., in case of gastrointestinal bleeding); consider possible surgical intervention or invasive procedures; add oral charcoal if the DOAC was recently ingested; and consider the use of a specific antidote or by pass hemostatic agents [prothrombin complex concentrates (PCC), 4 factors if available, or activated prothrombin complex concentrates (apcc), or rfviia]. Statistical analysis Descriptive analysis was performed. Continuous variables are expressed as median and interquartile (IQR) or as median and range. Categorical variables are expressed as frequencies and percentages. The SPSS software for Windows, version 22 (SPSS Inc, Chicago, IL), was used for data processing. Results Patient characteristics Between January 1, 2015 and December 31, 2016, 117 patients with major bleeding on DOACs were enrolled in the study: 32 patients were on apixaban (63 and 37% taking 5 or 2.5 mg twice-daily, respectively), 32 on dabigatran (75 and 25% taking 150 or 110 mg twice daily, respectively), 51 on rivaroxaban (61 and 39% taking 20 or 15 mg once-daily, respectively), and two on edoxaban (both taking 60 mg once-daily). The patient baseline characteristics, sites of major bleeding and outcomes are summarized in Table 1. NVAF was the main clinical indication (84%). Overall, 42% of patients who experienced major bleeding complications were on low-dose NOAC treatment, 11% were treated concomitantly with antiplatelet drugs, and 30% were previously shifted from AVK to DOACs. Time of last dose intake was available in 49% of patients and varied from 4 to 12 h. Bleeding characteristics Bleeding events occurred during the first 90 days of DOAC treatment in 45% of patients. The site of bleeding was intracranial in 53 patients (13 were fatal and one of them occurred in a patient treated concomitantly with ticagrelor and rivaroxaban), gastrointestinal in 42 (1 fatal), and 22 patients had major bleeding in other sites (Table 1). Of all bleeding events, 94 (80.4%) were spontaneous while 23 (19.6%) were post-traumatic. Within post-traumatic complications, we observed: 14/53 ICH (12 subdural, 1 lobar, and 1 deep), 2/42 gastrointestinal,and 7/7 muscular hematoma. In Table 2, the cases in whom it was possible to calculate whether the drug administered was under- or over-dosed are shown. Bleeding management The therapeutic strategies used for bleeding management are reported in Table 3. In summary: among the 117 patients, no therapeutic intervention was adopted in 34 (29%), while the other 83 patients (71%), received one or more than one of the therapies listed in Table 3. Idarucizumab 5gr/IV was administered in 3 out of 51 patients treated with dabigatran (5.8%): two with ICH and one with retroperitoneal hemorrhage. Management strategies for bleeding were considered to be adherent with what suggested by current international guidelines (10) in nearly 70% of them (see Table 3). Laboratory findings Table 4 shows the available data regarding the median levels (and range) measured before and after intervention (when available). Specific DOAC measurements, expressed as drug concentration equivalent (ng/ml), were available in only 23% of cases pre-treatment and 10% post-treatment. In only one patient with post-traumatic subdural ICH, plasma concentration of dabigatran was measured before (188 ng/ ml) and after (3 ng/ml) the administration of idarucizumab. The available individual results of specific drug measurements performed before and after intervention are shown in Table 5.
4 Table 1 Main clinical characteristics and outcomes of included patients Patients All 117 NVAF VTE Indication to anticoagulation, n (%) 99 (84) 18 (16) Males, n (%) 73 (62) Median age (IQR), years 79 (74,85) 80(75,86) 65 (70,77) History of previous bleeding, n (%) 10 (8.5) 5 (5) 5(38%) Anticoagulant drugs, n (%) Apixaban 32 (27.4) 29 3 Dabigatran 32 (27.4) 32 0 Rivaroxaban 51 (43.5) Edoxaban 2 (1.7) 1 1 Major bleeding, n (%) Spontaneous 94 (80.3) 76(76.7) 18(100) Intracranial 53 (45.3) 47 (47.4) 6 (33.3) Gastrointestinal 42 (35.9) 32(32.3) 10 (18.5) (Intra)muscular hematoma 7 (6.1) 6 (6.0) 1 (5.5) Retroperitoneal 4 (3.4) 4 (4.0) 0 Hematuria 3 (2.5) 3(3.0) 0 Retinal (intraocular) bleeding (loss of vision) 2 (1.7) 2 (2.0) 0 Pericardial 2(1.7) 1(1.0) 0 Metrorrhagia 1 (0.9) 1(1.0) 0 Other 4(2.5) 3(3.0) 1(5.5) Outcome at hospital discharge, n (%) 117 Complete resolution 87/117 (74) 72(71.7) 15(83) Disability (for ICH) 16/53 (30) 15(30) 1 Death 14/117 (11.9) 12 (12) 2(11.1) Outcome at 6 months, n (%) 102 a Complete resolution 86/102 (84.3) 71(84.0) 15 Disability (for ICH) 11/40 (27.5) 10 (25) 1 Death 4/102 (3.9) 4(4.6) 0 NVAF non-valvular atrial fibrillation, VTE venous thromboembolism, IQR interquartile, ICH intracranial hemorrhage a One patient with complete resolution at hospital discharge was lost at follow-up Outcomes at hospital discharge and at 6 months Table 2 Patients with underdosed or over-dosed drug in relation to age, gender, and creatinine level (only for patients with all data available) NVAF = 99 VTE = 18 Underdosed drugs Apixaban 6/10 1/3 Dabigatran 13/22 Rivaroxaban 6/24 Edoxaban Over-dosed drugs Apixaban Dabigatran 4/22 Rivaroxaban 6/24 Edoxaban Outcomes are summarized in Table 1. During hospitalization, 14 bleedings had a fatal outcome [11.9% of the total population: 13 ICH and 1 gastrointestinal (GI) bleeding], which occurred within 3 days after the acute event. At hospital discharge, 74% of all patients had complete resolution of signs of bleeding. When we consider ICH patients only, we observed complete resolution of symptoms in 24/53 patients (45.2%) and residual disability in 16/53 (30%). At 6 months, among the 102 patients discharged, the complete resolution of symptoms was recorded in 85% of them. Four patients (two ICH, one GI, and one retroperitoneal bleeding) died because of later thrombotic complication. In particular, we registered three acute myocardial infarctions (AMI): one in a patient with ICH treated with prophylactic dose of LMWH, who developed pneumonia, one with retroperitoneal bleeding treated with low-dose dabigatran, and
5 Table 3 Bleeding management and death at hospital discharge and at follow-up, according type of intervention and drug ICH n.53 GI n.42 Other n.22 Total n.117 Death 1 3 days n.14 No treatment n (%) 19 (36) 12 (28.6) 3 (13.6) 34 (29.1) 5 (35.7) 1 Apixaban Dabigatran Rivaroxaban Edoxaban 1 Symptomatic treatment a 0 17 (40.5) 9 (41.2) 26 (22.2) 2 Apixaban Dabigatran Rivaroxaban 8 1 Edoxaban 1 Antifibrinolytics 4 (7.5) (3.4) 3 (21.5) 0 Apixaban 1 Dabigatran 3 1 Rivaroxaban 2 Antidote (idarucizumab) 2 (3.8) 1 (4.5) 3 (2.6) PCC b 21 (39.6) 4 (9.5) 2 (9.0) 27 (23.0) 5 (35.7) 0 Apixaban Dabigatran Rivaroxaban Surgery + PCC 4 (7.5) 0 1 (4.5) 5 (4.3) 1 (7.1) 0 Apixaban 1 Dabigatran 2 1 Rivaroxaban 1 1 Death 6 mo. n.4 ICH intracranial hemorrhage a Includes fluid replacement ± red blood transfusion b Prothrombin complex concentrates ± antifibrinolytics, vitamin K, oral charcoal the third in a patient with GI bleeding and femoral fracture who suffered an AMI during treatment with low-dose apixaban. In addition, there was one sudden death in a patient with ICH who did not restart anticoagulation. The overall mortality of the entire cohort was 15.5%. During follow-up, after the temporary interruption of DOACs, 38 patients (37% of survivors) restarted anticoagulation with the same drug, four patients (3.9%) shifted to another DOAC, two (2%) did not restart anticoagulation, and among the remaining patients 35 (35%) were treated with prophylactic doses of low molecular weight heparin, whereas 22 received VKA (22%). Only one patient with NVAF restarted antithrombotic therapy with low dose of aspirin. In one patient with VTE, a vena cava filter was implanted, and in another case, the anticoagulant treatment was interrupted and intermittent pneumatic compression was adopted. Overall, 2/99 (2%) of patients who restarted anticoagulant therapy had recurrent bleeding, and 3/99 (3%) experienced thrombotic events; among those who did not restart anticoagulant therapies, no one had recurrent bleeding events and 1/2 (50%) had thrombotic events, respectively. Among the 22 patients who restarted anticoagulation with VKA, 13 (58%) had previously suffered GI bleeding and 2 (9%) ICH. Among the 42 patients who restarted anticoagulation with the DOACs, 14 (33%) had suffered GI bleeding and 11 (26%) ICH. No patients who resumed anticoagulation with VKA suffered major bleeding recurrence during 6 months of follow-up, whereas a recurrent major bleeding occurred in two patients who received DOACs (one was subsequently shifted to LMWH at prophylactic regimen, the other to VKA). Among the 42 patients with GI bleeding, cancer was diagnosed in 3 (7%, all colorectal cancer) who were previously asymptomatic. One patient with diagnosis of GI cancer, who had complete resolution of bleeding at hospital discharge, was lost to follow-up. Discussion The DOACs have been shown to be safe and effective drugs for the treatment of venous thromboembolism and stroke prevention in NVAF when compared to vitamin K
6 Table 4 Results of available laboratory measurements before and after acute treatments Assay, no. of patients (%) Before intervention Post intervention Median (range) Median (range) PT INR, 94/117(80) 1.12 ( ) NA aptt ratio, 95/117 (81) 1.47 ( ) 1.4 ( ) Hemoglobin 108/117 (92) 12.3 (6.3 14) NA Platelet count 104/117 (89) 228 (85 502) NA Creatinine clearance 89/ (44 80) NA (76) Dabigatran dtt (ng/ml) 269 ( ) 13.3 ( ) 5/32 a 3/32 a Dabigatran ECA (ng/ml) 699 NA 1/32 a Apixaban axa activity (ng/ ml) 161 (99 571) 70.6 (2 139) 8/32 a 5/32 a Rivaroxaban axa activity 134 (24 369) 23 (0 71) 13/51 a 6/51 a PT prothrombin time, aptt activated partial thromboplastin time, DTT diluted thrombin time, ECA ecarin clotting time, INR international normalized ratio, NA not available a Number of specific NOAC measurements related to the number of patients treated with the same drug antagonists. However, as for all anticoagulant drugs, major spontaneous or post-traumatic bleedings may occur during DOAC treatment. Due to the increasing prevalence of patients who are treated with DOACs in the general population, major bleedings will become a relatively frequent event in the emergency departments with an urgent need for improving diagnostic and therapeutic tools, and specific strategies related to the site of bleeding, type of drugs, anticoagulant levels, necessity of surgical, or interventional procedures [11, 25]. Since patients are admitted to emergency departments after variable hours from the last DOAC dose intake and may present with several comorbidities, anticoagulant activity may not be exclusively predictable on the basis of the drug half-life and the evaluation of renal function, also because of the high inter intra plasma level variability [26]. This study aims to describe how clinicians manage, at present, major bleeding complications in patients treated with DOACs. In the study, 117 patients with major bleedings are included, prevalently ICH and GI (45.3 and 35.9%, respectively) occurring in elderly NAVF or VTE patients. Most deaths in ICH patients (13/14; 92.8%) occur within the first 72 h from hospital admission. ICH-related mortality is 26.4%, similar to what is recently reported in the literature [27]. As shown in previous studies [27 29], ICH mortality in DOACs seems lower than in AVK, but, in any case, it concerns nearly one-fourth of total ICH in DOAC-treated patients. Table 5 Results of available individual specific laboratory measurements obtained before and after acute treatments Patient, drug used, assay Before intervention Post intervention Dabigatran DTT (ng/ml) (antidote) Apixaban axa activity (ng/ml) a a a a a Rivaroxaban axa activity (ng/ml) a b b b a a Patients in whom PCC4F were administered b Patients in whom PCC3F were administered In this study, we observe that nearly 50% of the total population received no treatment or symptomatic support only. Among ICH patients, nearly 30% were solely managed with interruption of DOAC administration and clinical monitoring. The high mortality and disability rates associated to ICH bleeding strongly indicate a need for a rapid normalization of hemostasis. An approach only based on the evaluation of renal function and drug half-life may not guarantee a rapid normalization of hemostasis. We observe that symptomatic treatment is prevalently used in extra-cerebral bleedings, whereas PCCs, antifibrinolytic agents, and antidotes are mainly used in ICH bleedings. Fresh frozen plasma was used as symptomatic treatment in 22.2% of patients, all of them with extracranial bleedings, and three patients received vitamin K, which is not useful to reverse a DOAC activity. More than 30% of the included patients were not treated in accordance with the international guidelines, mainly
7 because they did not receive any specific treatment except for clinical surveillance (see Table 3). The therapeutic approaches among the study patients vary even when the site and severity of bleeding were the same, suggesting the absence of universally applied protocols. During the 6-month follow-up, four deaths were observed due to thrombotic complications and accounting for the 3.9% of the total deaths. Bleeding case fatality rate is 11.9% and death occurred in 15.4% of the total population. Only toward the end of our observational study was idarucizumab licensed in European countries. This explains why only 3 out of 53 dabigatran-treated patients received the reversal agent. We observe that only in one case, the antidote was administered after DOAC-specific measurement, opening the question about the risk of its overuse [30 32]. Clinicians requested laboratory tests, including blood cell count and screening coagulation test, in nearly 80% of patients, whereas specific DOAC measurements were obtained in only 23% of them, indicating that bleeding treatments were administered independently from objectively defined hemostatic assessment. This observation opens the question about the importance of laboratory testing in emergency clinical conditions to address appropriate treatments. As previously shown [21], global coagulation tests such as PT and aptt are not useful to quantify DOAC activity, while specific tests (anti-xa, dtt, ecarin test) are available and easily adaptable on most commercial coagulation platform. Despite the increasing consensus on the need for DOAC measurement in specific clinical conditions, our study shows a low rate of specific drug measurements in emergency situations, highlighting an urgent need for their implementation in each hospital. In general, the approach to major bleeding in anticoagulated patients should be based on two main cornerstones: (1) symptomatic treatment of blood loss and treatment of the anatomical cause of bleeding and (2) reversal of the hemostatic impairment due to the anticoagulant drug, if present. In this perspective, laboratory testing and specific drug measurements should guide the management of patients. Large phase III clinical studies [2 6] and post-marketing analysis [33, 34] indicate that major bleeding with the DOACs is associated with a more favorable outcome than with the vitamin K antagonists. Nevertheless, in the present study, major bleeding during DOAC treatment accounts for 15% of deaths and 24% of disability, suggesting that all efforts should be done to improve the management of major bleeding in DOAC-anticoagulated patients. This study has several limitations. The most important is the small number of patients with major bleeding included; this makes it necessary to be very cautious in evaluating the recorded results. Furthermore, the time span for inclusion of cases was large and differences in patient management during this interval time can be expected. Obviously, the design of the study did not allow the collection of any data on the prevalence of bleedings and on the effect of different DOACs. We believe this experience highlights the following needs: (1) homogeneous and more structured guidelines; (2) available reversal agents; (3) DOAC-specific measurements, rapidly available in emergency; (4) specific training on anticoagulation reversal for emergency department physicians; and (5) available consultants expert on thrombosis and haemostasis, who may ensure upgraded, homogeneous, and probably more effective management of acute major bleeding complications in anticoagulated patients. List of participating centers and number of enrolled patients Sophie Testa, Oriana Paoletti, Haemostasis and Thrombosis Center, Ospedale di Cremona (20). Jan Beyer-Westendorf, Dresden University Clinic (15). Maurizio Paciaroni, Stroke Unit, Università di Perugia (14). Peter Verhamme, UZ Gasdthuisberg, Leuven (11). Daniela Poli, Elisa Grifoni, Thrombosis Centre, AOU Careggi, Firenze (8). Walter Ageno, Giovanna Colombo, Medicina I Osp di Circolo, Università dell Insubria, Varese (7). Vittorio Pengo, Cardiology Clinic, Thrombosis Centre, Department of Cardiac, Thoracic and Vascular Sciences, University of Padua (7). Marc Righini, Division of Angiology and Hemostasis Genèva University Hospital (7). Piera Sivera, Ospedale Mauriziano Torino (7). Ponlapat Rojnuckarin, Chulalongkorn University, Bangkok (5). Wang Tzu-Fei, The Ohio State University (5). Giuliana Guazzaloca, Ludovica Migliaccio, Angiology Blood Coagulation, University Hospital Sant Orsola Malpighi Bologna (5). Bruno Caramelli, University of Sao Paulo (3). Michela Provisione, Medicina II Ospedale Busto Arsizio, Varese (2). Alberto Tosetto, S. Bortolo Hospital, Vicenza (1). Funding The Arianna Anticoagulation Foundation supported the START Register and the study. The Foundation had no role in study design, collection, analysis, and interpretation of data, in writing the report, and in the decision to submit the paper for publication. Compliance with ethical standards Conflict of interest The Authors declare that they have no conflict of interest.
8 Statement of human and animal rights All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional or national research committee and with the 1964 Helsinki Declaration, and its later amendments or comparable ethical standards. Informed consent All patients enrolled in the study have read and signed the informed consent. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( iveco mmons.org/licen ses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. References 1. Ageno W, Gallus AS, Wittkowsky A, ACCP et al (2012) Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141:e44S e88s 2. Connolly SJ, Ezekowitz MD, Yusuf S, RE-LY Steering Committee and Investigators et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361: Patel MR, Mahaffey KW, Garg J et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365: Granger CB, Alexander JH, McMurray JJ, ARISTOTLE Committees Investigators et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365: Giugliano RP, Ruff CT, Braunwald E, ENGAGE AF-TIMI 48 Investigators et al (2013) Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369: Ruff CT, Giugliano RP, Braunwald E et al (2014) Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383: Eriksson BI, Quinlan DJ, Weitz JI (2009) Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development. Clin Pharmacokinet 48: Prisco D, Ageno W, Becattini C et al (2017) Italian intersociety consensus on DOAC use in internal medicine. Intern Emerg Med 1: Pengo V, Crippa L, Falanga A et al (2011) Questions and answers on the use of dabigatran and prospectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Center (FCSA). Thromb Haemost 106: Baglin T (2013) The role of the laboratory in treatment with new oral anticoagulants. J Thromb Haemost 11 (Suppl 1): Heidbuchel H, Verhamme P, Alings M et al (2015) Updated European Heart Rhythm Association Practical Guide on the use of nonvitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace 17: Kitchen S, Gray E, Mackie I, Baglin T et al (2014) Measurement of non-coumarin anticoagulants and their effects on test of haemostasis: guidance from the British Committee for Standards in Haematology. Br J Haematol 166: Tripodi A, Marongiu F, Moia M et al (2018) The vexed question of whether or not to measure levels of direct oralanticoagulants before surgery or invasive procedures. Intern Emerg Med. https ://doi.org/ /s (Epub ahead of print) 14. Beyer-Westendorf J, Förster K, Pannach S et al (2014) Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood 124: Pollack CV Jr, Reilly PA, Eikelboom J et al (2015) Idarucizumab for dabigatran reversal. N Engl J Med 373: Husted S, Verheugt FW, Comuth WJ (2016) Reversal strategies for NOACs: state of development, possible clinical applications and future perspectives. Drug Saf 39: Connolly SJ, Milling TJ Jr, Eikelboom JW, ANNEXA-4 Investigators et al (2016) Andexanet Alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med 375: Ansell JE, Bakhru SH, Laulicht BE et al (2014) Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med 2014(371): Siegal DM, Cuker A (2014) Reversal of target-specific oral anticoagulants. Drug Discov Today 19: Antonucci E, Poli D, Tosetto A et al (2015) The Italian STARTregister on anticoagulation with focus on atrial fibrillation. PLoS One 10:e Testa S, Legnani C, Tripodi A et al (2016) Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter/ multiplatform study. J Thromb Haemost 14: Douxfils J, Mani H, Minet V et al (2015) Non-VKA oral anticoagulants: accurate measurement of plasma drug concentrations. Biomed Res Int 2015: Schulman S, Kearon C (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3: Mahoney FI, Barthel DW (1965) Functional evaluation: the Barthel index. Md State Med J 14: Marongiu F, Barcellona D (2018) Direct oral anticoagulants: what can we learn? Intern Emerg Med. https ://doi.org/ /s (Epub ahead of print) 26. Testa S, Legnani C, Pengo V et al (2015) Plasma levels of direct oral anticoagulants in real life patients with atrial fibrillation: results observed in four anticoagulation clinics. Tromb Res 137: Becattini C, Franco L, Beyer-Westendorf J et al (2017) Major bleeding with vitamin K antagonists or direct oral anticoagulants in real-life. Int J Cardiol 227: Veltkamp R, Rizos T, Horstmann S (2013) Intracerebral bleeding in patients on antithrombotic agents. Semin Thromb Hemost 39: Cucchiara B, Messe S, Sansing L et al (2008) Hematoma growth in oral anticoagulant related intracerebral hemorrhage. Stroke 39: Bauer KA (2015) Targeted anti-anticoagulants. N Engl J Med 373: Weitz JI, Eikelboom JW (2016) Urgent need to measure effects of direct oral anticoagulants. Circulation 134: Levy JH, Ageno W, Chan NC et al (2016) When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. J Thromb Haemost 14: Xu Y, Schulman S, Dowlatshahi D et al (2017) Direct oral anticoagulant- or warfarin-related major bleeding: characteristics, reversal strategies and outcomes from a multi-center observational study. Chest 152: Wilson D, Seiffge DJ, Traenka C et al (2017) Outcome of intracerebral hemorrhage associated with different oral anticoagulants. Neurology 88:
COAGULATION TESTING AND NEW ORAL ANTICOAGULANTS
COAGULATION TESTING AND NEW ORAL ANTICOAGULANTS SOPHIE TESTA Haemostasis and Thrombosis Center ASST-Cremona, Italy ANTICOAGULANT DRUGS Eikelboom JW, Weitz JI. Circulation 2010;6:1523-32 DRUGS UH LAB aptt
More informationMANAGING DOACs IN REAL LIFE. SOPHIE TESTA Haemostasis and Thrombosis Center Istituti Ospitalieri Cremona, Italy
MANAGING DOACs IN REAL LIFE SOPHIE TESTA Haemostasis and Thrombosis Center Istituti Ospitalieri Cremona, Italy ITEMS The State of the Art in summary Guidelines recommendations Which useful evidence from
More informationTrue/False: Idarucizumab can be utilized for the management of bleeding associated with dabigatran.
Discuss the role of idarucizumab for the management of bleeding associated with dabigatran Understand dosing, preparation and administration of idarucizumab I have no financial interest/arrangement or
More informationDiscuss the role of idarucizumab for the management of bleeding associated with dabigatran
Discuss the role of idarucizumab for the management of bleeding associated with dabigatran Understand dosing, preparation and administration of idarucizumab I have no financial interest/arrangement or
More information3/25/2016. Objectives for Pharmacists. Stop the Bleeding! New Reversal Agents. Objectives for Pharmacy Technicians. Assessment Pre-test
Objectives for Pharmacists Stop the Bleeding! New Reversal Agents Gary D Peksa, Pharm.D., BCPS Clinical Pharmacy Specialist, Emergency Medicine Rush University Medical Center Review current strategies
More informationDirect Oral Anticoagulant Reversal
08 June 2018 No. 08 Direct Oral Anticoagulant Reversal M Khattab Moderator: E Hodgson School of Clinical Medicine Discipline of Anaesthesiology and Critical Care CONTENTS INTRODUCTION... 3 Pharmacokinetics
More informationReversal Agents for NOACs (Novel Oral Anticoagulants)
Reversal Agents for NOACs (Novel Oral Anticoagulants) Current status and future challenges Paul A Reilly, PhD Clinical Research, Boehringer Ingelheim, Inc CSRC Symposium Washington DC Oct 18, 2016 Atrial
More informationUpdates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism
Disclosures Updates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism No financial conflicts of interest Member of the ABIM Focused- Practice in Hospital Medicine Self Examination Process
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC DEBATE: DOAC vs Good Old Warfarin André Roussin MD, FRCP, CSPQ CHUM and ICM/MHI Associate professor University of Montreal A. Roussin
More informationNew Options for Anticoagulation Reversal: A Practical Approach
New Options for Anticoagulation Reversal: A Practical Approach Hyung Wook Park Chonnam National University Hospital, Gwangju, Korea 4 NOACs Prevention of TE No. of events (%/yr..) NOAC Warfarin HR 95%
More informationThe Direct Oral Anticoagulants: Practical Considerations. David Garcia, MD University of Washington Seattle Cancer Care Alliance September 2015
The Direct Oral Anticoagulants: Practical Considerations David Garcia, MD University of Washington Seattle Cancer Care Alliance September 2015 Disclosure Occasional consultant to : BMS, Pfizer, Daiichi
More informationReversal of Novel Oral Anticoagulants. Angelina The, MD March 22, 2016
Reversal of Novel Oral Anticoagulants Angelina The, MD March 22, 2016 Argatroban Bivalirudin Enoxaparin Lepirudin Heparin Dabigatran Apixaban 1939 1954 1998 2000 1999 2001 10/2010 7/2011 12/2012 1/2015
More informationAndexanet alfa in Factor Xa Inhibitor-Associated Acute Major Bleeding
Andexanet alfa in Factor Xa Inhibitor-Associated Acute Major Bleeding Stuart J. Connolly, M.D., Truman J. Milling, Jr., M.D., John W. Eikelboom, M.D., C. Michael Gibson, M.D., John T. Curnutte, M.D., Ph.D.,
More informationBLOOD DISEASE RESEARCH FOUNDATION
BLOOD DISEASE RESEARCH FOUNDATION BLOOD DISEASE RESEARCH FOUNDATION The mission of Blood Disease Research Foundation is to support hematological research, e.g. by donating grants for thesis work and abstract
More informationGuidance for management of bleeding in patients taking the new oral anticoagulant drugs: rivaroxaban, dabigatran or apixaban
Guidance for management of bleeding in patients taking the new oral anticoagulant drugs: rivaroxaban, dabigatran or apixaban Purpose The aim of this guidance is to outline the management of patients presenting
More informationWhat s new with DOACs? Defining place in therapy for edoxaban &
What s new with DOACs? Defining place in therapy for edoxaban & Use of DOACs in cardioversion Caitlin M. Gibson, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy University of North Texas
More informationReversal of direct oral anticoagulants in the patient with GI bleeding. Marc Carrier
Reversal of direct oral anticoagulants in the patient with GI bleeding Marc Carrier Disclosure Faculty: Dr. Marc Carrier Relationships with commercial interests: Grants/Research Support: Leo Pharma, Bristol
More informationManaging Bleeding in the Patient on DOACs
Managing Bleeding in the Patient on DOACs Spring 2016 Jean M. Connors, MD Anticoagulation Management Services BWH/DFCI Hemostatic Antithrombotic Stewardship BWH Assistant Professor of Medicine, HMS Conflicts
More informationIntroduction. Blood Pressure
Introduction Spontaneous intracerebral hemorrhage (ICH) is a major cause of morbidity and mortality worldwide [1]. Of a number of factors that have been linked to ICH (e.g., higher rates in Asians and
More informationContent 1. Relevance 2. Principles 3. Manangement
Intracranial haemorrhage and anticoagulation Department of Neurology,, Germany Department of Neurology, Heidelberg University Hospital, Germany Department of Clinical Medicine Copenhagen University, Denmark
More informationNeuroPI Case Study: Anticoagulant Therapy
Case: An 82-year-old man presents to the hospital following a transient episode of left visual field changes. His symptoms lasted 20 minutes and resolved spontaneously. He has a normal neurological examination
More informationIncidence and Impact of Antithrombotic-related Intracerebral Hemorrhage
Incidence and Impact of Antithrombotic-related Intracerebral Hemorrhage John J. Lewin III, PharmD, MBA, BCCCP, FASHP, FCCM, FNCS Division Director, Critical Care & Surgery Pharmacy Services, The Johns
More informationManaging Hemorrhagic Complications of Non-Vitamin K Antagonist Oral Anticoagulants
Managing Hemorrhagic Complications of Non-Vitamin K Antagonist Oral Anticoagulants MICHAEL E. MULLINS MD FAACT FACEP Washington University School Of Medicine Chair, BJH Anticoagulation Subcommittee Chair,
More informationAnticoagulation with Direct oral anticoagulants (DOACs) and advances in peri-procedural interruption of anticoagulation-- Bridging
Anticoagulation with Direct oral anticoagulants (DOACs) and advances in peri-procedural interruption of anticoagulation-- Bridging Scott C. Woller, MD Co-Director, Thrombosis Program Intermountain Medical
More informationReversal of Action: Addressing the Unmet Need for Universal Antidotes to Factor Xa Anticoagulants. Disclosures
Reversal of Action: Addressing the Unmet Need for Universal Antidotes to Factor Xa Anticoagulants Daniel Pallin, MD, MPH Harvard Medical School Brigham and Women s Hospital Boston, Massachusetts Disclosures
More informationUSE OF DIRECT ORAL ANTICOAGULANTS IN OBESITY
SDSHP ANNUAL MEETING CLINICAL PEARLS APRIL 7 TH, 2017 USE OF DIRECT ORAL ANTICOAGULANTS IN OBESITY STEFFANIE DANLEY, PHARM D, BCPS, CACP DISCLOSURE I have had no financial relationship over the past 12
More informationEmergency Management of Patients on Direct Oral Anticoagulants (DOACs)
Emergency Management of Patients on Direct Oral Anticoagulants (DOACs) Dr Tina Biss Consultant Haematologist Newcastle upon Tyne Hospitals NHS Foundation Trust NE RTC Annual Education Symposium 11 th October
More informationIndividual Therapeutic Selection Of Anti-coagulants And Periprocedural. Miguel Valderrábano, MD
Individual Therapeutic Selection Of Anti-coagulants And Periprocedural Management Miguel Valderrábano, MD Outline Does the patient need anticoagulation? Review of clinical evidence for each anticoagulant
More informationNOACS/DOACS*: COAGULATION TESTS
NOACS/DOACS*: COAGULATION TESTS OBJECTIVES: To describe the effect of the newer direct oral anticoagulants (DOACs) on laboratory coagulation tests which are widely available: prothrombin time (PT), international
More information6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia
6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia October 31 st - November 1 st, 2015 NOACS vs. Coumadin in Atrial Fibrillation: Is It Worth to Switch? Raed Sweidan, MD, FACC Consultant and Head of Cardiac
More informationPros and Cons of Individual Agents Based on Large Trial Results: RELY, ROCKET, ARISTOTLE, AVERROES
Pros and Cons of Individual Agents Based on Large Trial Results: RELY, ROCKET, ARISTOTLE, AVERROES Ralph L. Sacco, MS MD FAAN FAHA Olemberg Family Chair in Neurological Disorders Miller Professor of Neurology,
More informationThe INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center
The INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center What is the INR? Tissue Factor (Factor III) is added to
More informationDirect Oral Anticoagulants (DOACs). Dr GM Benson Director NI Haemophilia Comprehensive Care Centre and Thrombosis Unit BHSCT
Direct Oral Anticoagulants (DOACs). Dr GM Benson Director NI Haemophilia Comprehensive Care Centre and Thrombosis Unit BHSCT OAC WARFARIN Gold standard DABIGATRAN RIVAROXABAN APIXABAN EDOXABAN BETRIXABAN
More informationLatest News and Clinical Applications of NOACs: What about Antidotes?
Optimizing outcomes in Atrial Fibrillation Latest News and Clinical Applications of NOACs: What about Antidotes? McMaster Cardiology Update September 11, 2015 Agenda Real world data on the use of NOACs
More informationNOACs for Primary and Secondary Stroke Prevention: From Clinical Trials to Real-World Data To Practical Considerations
NOACs for Primary and Secondary Stroke Prevention: From Clinical Trials to Real-World Data To Practical Considerations Mark J. Alberts, MD, FAHA Hartford HealthCare Hartford, CT USA AF confers an increased
More informationINR as a Biomarker: Anticoagulation in Atrial Fib, Heart Failure, and Cardiovascular Disease Daniel Blanchard, MD, FACC, FAHA
INR as a Biomarker: Anticoagulation in Atrial Fib, Heart Failure, and Cardiovascular Disease Daniel Blanchard, MD, FACC, FAHA Professor of Medicine Director, Cardiology Fellowship Program Sulpizio Cardiovascular
More informationBleeding Complications in Patients Receiving Direct Oral Anticoagulant Therapy in the Post Clinical Trial General Practice
American Journal of Clinical and Experimental Medicine 2017; 5(3): 64-68 http://www.sciencepublishinggroup.com/j/ajcem doi: 10.11648/j.ajcem.20170503.12 ISSN: 2330-8125 (Print); ISSN: 2330-8133 (Online)
More informationDebate: New Generation Anti-Coagulation Agents are a Better Choice than Warfarin in the Management of AF
Debate: New Generation Anti-Coagulation Agents are a Better Choice than Warfarin in the Management of AF Bradley P. Knight, MD Director of Cardiac Electrophysiology Bluhm Cardiovascular Institute Northwestern
More informationReversal Agents for Anticoagulants Understanding the Options. Katisha Vance, MD, FACP Alabama Oncology January 28, 2017
Reversal Agents for Anticoagulants Understanding the Options Katisha Vance, MD, FACP Alabama Oncology January 28, 2017 Objectives Appropriately recommend reversal agents for Vitamin K antagonists Appropriately
More informationDIRECT ORAL ANTICOAGULANTS
2017 Cardiovascular Symposium DIRECT ORAL ANTICOAGULANTS ERNESTO UMAÑA, MD, FACC ORAL ANTICOAGULANTS Vitamin K Antagonists (VKAs): Warfarin Non Vitamin K Antagonists Direct oral anticoagulants Novel Oral
More informationNEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS
NEW/NOVEL ORAL ANTICOAGULANTS (NOACS): COMPARISON AND FREQUENTLY ASKED QUESTIONS OBJECTIVES: To provide a comparison of the new/novel oral anticoagulants (NOACs) currently available in Canada. To address
More informationWarfarin for Long-Term Anticoagulation. Disadvantages of Warfarin. Narrow Therapeutic Window. Warfarin vs. NOACs. Challenges Monitoring Warfarin
1 2:15 pm The Era of : Selecting the Best Approach to Treatment SPEAKER Gregory Piazza, MD, MS Presenter Disclosure Information The following relationships exist related to this presentation: Gregory Piazza,
More informationAnticoagulation Task Force
Anticoagulation Task Force Newest Recommendations Donald Zabriskie, BPharm, MBA, RPh Pharmacy Patient Care Services Cleveland Clinic- Fairview Hospital THE DRUGS THE PERFECT ANTICOAGULANT Oral administration
More informationAnticoagulation Beyond Coumadin
Anticoagulation Beyond Coumadin Saturday, September 21, 2013 Crystal Mountain Resort and Spa Pratik Bhattacharya MD, MPH Stroke Neurologist, Michigan Stroke Network; Assistant Professor of Neurology; Wayne
More informationChapter 1 Introduction
Chapter 1 Introduction There are several disorders which carry an increased risk of thrombosis, clots that interfere with normal circulation, including: venous thromboembolism (VTE), comprising both deep
More informationHaematology Subcommittee of PTAC Meeting held 16 March 2016
Haematology Subcommittee of PTAC Meeting held 16 March 2016 (minutes for web publishing) The Haematology Subcommittee minutes are published in accordance with the Terms of Reference for the Pharmacology
More informationREVERSAL STRATEGIES FOR ORAL ANTICOAGULATION
REVERSAL STRATEGIES FOR ORAL ANTICOAGULATION Wesley R. Zemrak, Pharm.D., BCPS Clinical Pharmacy Specialist, Anticoagulation Maine Medical Center, Portland, ME zemraw@mmc.org 1 OBJECTIVES 1. Discuss the
More informationRole of NOACs in AF Management. From Evidence to Real World Data Focus on Cardioversion
Role of NOACs in AF Management. From Evidence to Real World Data Focus on Cardioversion John Rickard MD, MPH Staff Electrophysiologist Cleveland Clinic Agenda NOACs: Update on Real World Data NOAC reversal:
More informationACCP Cardiology PRN Journal Club
ACCP Cardiology PRN Journal Club 1 Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation and Valvular Heart Disease Cody A. Carson, PharmD, BCPS PGY2 Cardiology Pharmacy Resident
More informationEvidences for real-life use in fragile patients: Renal failure and cancer
Evidences for real-life use in fragile patients: Renal failure and cancer Cecilia Becattini Medicina Interna e Cardiovascolare Stroke Unit Università di Perugia Approval number: L.IT.MA.11.2016.1839 Evidences
More informationAtrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015
Atrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015 Christopher E. Bauer, MD, FACC, FHRS SSM Health Heart & Vascular Care Clinical Cardiac Electrophysiology
More informationClinical issues which drug for which patient
Anticoagulants - a matter of heart! Towards a bright future? Clinical issues which drug for which patient Sabine Eichinger Dept. of Medicine I Medical University of Vienna/Austria Conflicts of interest
More informationOral Anticoagulants Update. Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation
Oral Anticoagulants Update Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation Objectives List the direct oral anticoagulant (DOAC) drugs currently available Describe
More informationKCS Congress: Impact through collaboration
Stroke Prevention in Atrial Fibrillation (SPAF) in Kenya Elijah N. Ogola FACC University of Nairobi Kenya Cardiac Society Annual Scientific Congress Mombasa 28 th June 1 st July 2017 KCS Congress: Impact
More informationÈ possibile cambiare posologia o farmaco sulla base dei test di laboratorio?
È possibile cambiare posologia o farmaco sulla base dei test di laboratorio? Armando D Angelo Servizio di Coagulazione ed Unità Ricerca Trombosi, IRCCS Ospedale San Raffaele, Milano XXVI CONGRESSO NAZIONALE
More informationClinical aspects of venous thromboembolism in special patient populations Bleker, S.M.
UvA-DARE (Digital Academic Repository) Clinical aspects of venous thromboembolism in special patient populations Bleker, S.M. Link to publication Citation for published version (APA): Bleker, S. M. (2017).
More informationAnticoagulation: Novel Agents
Anticoagulation: Novel Agents Scott C. Woller, MD Medical Director, Anticoagulation Management, Intermountain Healthcare Central Region, co-director Venous Thromboembolism Program, Intermountain Medical
More informationThe INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center
The INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center What is the INR? Tissue Factor (Factor III) is added to
More information2 Jean-Pierre Baeyens European Union Geriatric Medicine Society (EUGMS) representative
26 June 2014 Committee for Medicinal Products for Human Use (CHMP) Overview of comments received on 'Guideline on clinical investigation of medicinal products for prevention of stroke and systemic embolic
More informationThe Anticoagulated trauma patient in the age of the direct oral anticoagulants: a Canadian perspective
Wood et al. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine (2017) 25:76 DOI 10.1186/s13049-017-0420-y ORIGINAL RESEARCH The Anticoagulated trauma patient in the age of the direct
More informationReversal of DOACs Breakthroughs and Their Aftermath
Reversal of DOACs Breakthroughs and Their Aftermath Geno J Merli, MD, MACP, FSVM, FHM Professor Medicine & Surgery Co-Director Jefferson Vascular Center Sidney Kimmel Medical College Thomas Jefferson University
More informationNUOVI ANTICOAGULANTI NELL ANZIANO: indicazioni e controindicazioni. Mario Cavazza Medicina d Urgenza Pronto Soccorso AOU di Bologna
NUOVI ANTICOAGULANTI NELL ANZIANO: indicazioni e controindicazioni Mario Cavazza Medicina d Urgenza Pronto Soccorso AOU di Bologna Two major concerns Atrial Fibrillation: Epidemiology The No. 1 preventable
More informationA VENOUS THROMBOEMBOLISM (VTE) TOWN HALL: Answering Your Top Questions on Treatment and Secondary Prevention
A VENOUS THROMBOEMBOLISM (VTE) TOWN HALL: Answering Your Top Questions on Treatment and Secondary Prevention This handout is a supplemental resource to an educational video activity released on Medscape
More informationNOACS/DOACS*: COMPARISON AND FREQUENTLY-ASKED QUESTIONS
NOACS/DOACS*: COMPARISON AND FREQUENTLY-ASKED QUESTIONS OBJECTIVES: To provide a comparison of the newer direct oral anticoagulants (DOACs) currently available in Canada. To address frequently-asked questions
More informationNew Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY
New Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY Fact VTE is deadly! It nibbles after it bites! The 30-day mortality rates for first-time DVT or
More informationNovel Oral An,coagulants: Prac,cal Aspects. Caroline Berube, MD Clinical Associate Professor Division of Hematology November 2015
Novel Oral An,coagulants: Prac,cal Aspects Caroline Berube, MD Clinical Associate Professor Division of Hematology November 2015 The New Oral An,coagulants (NOACs) The Non VKA Oral An,coagulants (NOACs)
More informationNew Anticoagulants Therapies
New Anticoagulants Therapies Rachel P. Rosovsky, MD, MPH October 22, 2015 Conflicts of Interest No disclosures 2 Agenda 3 Historical perspective Novel oral anticoagulants Stats Trials Approval Concerns/Limitations
More informationControversies in Anticoagulation : Optimizing Outcome in NOACs for GI Bleeding Risk
Controversies in Anticoagulation : Optimizing Outcome in NOACs for GI Bleeding Risk Boyoung Joung, MD, PhD Professor, Division of Cardiology Director of Electrophysiology Laboratory Severance Cardiovascular
More informationlaboratory monitoring of Direct Oral Anticoagulant: who, when and how Dr. Malake Naboulsi Hôpital Albert Haykel Laboratoire d hématologie.
laboratory monitoring of Direct Oral Anticoagulant: who, when and how Dr. Malake Naboulsi Hôpital Albert Haykel Laboratoire d hématologie. Disclosures Malake Naboulsi declare to meeting attendees that
More informationIschemic and hemorrhagic strokes in the context of the direct acting oral anticoagulants
Ischemic and hemorrhagic strokes in the context of the direct acting oral anticoagulants Van Hellerslia, PharmD, BCPS, CACP Clinical Assistant Professor Temple University School of Pharmacy Over 4 million
More informationAfib, Stroke, and DOAC. Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS
Afib, Stroke, and DOAC Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS Disclosure of Relevant Financial Relationships I have no relevant financial relationships with commercial
More informationAnticoagulant-related Bleeding Management Order Set
Triage This icon represents guidance recommended by Thrombosis Canada Priority: Determine Bleeding Acuity: Minor, Moderate or Severe Bleeding Check one of the Following Levels of Bleeding Acuity (check
More informationIdarucizumab for Dabigatran Reversal Pollack CV, Reilly PA, Eikelboom J, et al. N Engl J Med 2015; 373(6):
Idarucizumab for Dabigatran Reversal Pollack CV, Reilly PA, Eikelboom J, et al. N Engl J Med 2015; 373(6):511-520. Objective: To measure the safety of idarucizumab to reverse dabigatran anticoagulant effects
More informationDOAC the story so far... Dr GM Benson Director NI Haemophilia and Thrombosis Centre BHSCT
DOAC the story so far... Dr GM Benson Director NI Haemophilia and Thrombosis Centre BHSCT A rose by any other name.. Recommendation on the nomenclature for oral anticoagulants: communication from the SSC
More information3/19/2012. What is the indication for anticoagulation? Has the patient previously been on warfarin? If so, what % of the time was the INR therapeutic?
Abigail E. Miller, PharmD, BCPS Clinical Specialist, Cardiology University of North Carolina Hospitals I have no personal financial relationships with the manufacturers of the products to disclose. Boehringer
More informationUpdate on Oral Anticoagulants. Dr. Miten R. Patel Cancer Specialists of North Florida Cell
Update on Oral Anticoagulants Dr. Miten R. Patel Cancer Specialists of North Florida Cell 904-451-9820 Email miten.patel@csnf.us Overview Highlights of the 4 new approved oral anticoagulants Results from
More informationAtrial fibrillation and anticoagulation JIR-PING BOEY, DEPARTMENT OF HAEMATOLOGY, FLINDERS MEDICAL CENTRE FEBRUARY 2016
1 Atrial fibrillation and anticoagulation JIR-PING BOEY, DEPARTMENT OF HAEMATOLOGY, FLINDERS MEDICAL CENTRE FEBRUARY 2016 Disclosures 2 No conflicts of interest Some questions 3 Should my patient with
More informationDr Shikha Chattree Haematology Consultant Sunderland Royal infirmary
Dr Shikha Chattree Haematology Consultant Sunderland Royal infirmary Increasing use of Novel Oral Anticoagulants (NOACs) in the management of prophylaxis and management of venous thromboembolism and in
More informationLa gestione dell ictus ischemico o emorragico nel paziente sotto NAO
La gestione dell ictus ischemico o emorragico nel paziente sotto NAO Antonio Carolei e Cindy Tiseo Clinica Neurologica e Stroke Unit Avezzano - Sulmona Università degli Studi dell Aquila Abano Terme, 10
More informationMonitoraggio di laboratorio dei NOA: NO
Monitoraggio di laboratorio dei NOA: NO Daniela Poli Firenze Vietri 8 Ottobre 2016 Ruff C, Lancet 2013 Stroke or systemic embolic events Dabigatran 150 mg bid Rivaroxaban 20 mg od Apixaban 5 mg bid Edoxaban
More informationNOAC: Future perspectives: academic perspective. Prof. Hugo ten Cate Maastricht University Medical Centre Maastricht the Netherlands
NOAC: Future perspectives: academic perspective Prof. Hugo ten Cate Maastricht University Medical Centre Maastricht the Netherlands To discuss Lessons from the NOAC-VKA studies and optimal VKA management
More informationIndications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute
Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute Disclosures Research Support/P.I. Employee Leo Pharma
More informationOld and New Anticoagulants For Stroke Prevention Benefits and Risks
Old and New Anticoagulants For Stroke Prevention Benefits and Risks September 15, 2014 Jonathan L. Halperin, M.D. The Cardiovascular Institute Mount Sinai Medical Center Disclosure Relationships with Industry
More informationDo s and Don t of DOACs DISCLOSURE
Do s and Don t of DOACs Tom DeLoughery, MD MACP FAWM Oregon Health and Sciences University DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau - None Consultant/Research none Content Expert: Elsevier
More informationNOACs in AF. Dr Colin Edwards Auckland Heart Group and Waitemata DHB. Dr Fiona Stewart Auckland Heart Group and Auckland DHB
NOACs in AF Dr Colin Edwards Auckland Heart Group and Waitemata DHB Dr Fiona Stewart Auckland Heart Group and Auckland DHB Conflict of Interest Dr Fiona Stewart received funding from Pfizer to attend the
More informationAntithrombotics in the elderly. Robert Gabor Kiss FESC FACC Budapest
Antithrombotics in the elderly Robert Gabor Kiss FESC FACC Budapest The patient in the elderly You are sitting in Your office prescribing drugs and observing outcome The black box from prescription to
More informationStroke Prevention and Treatment: New Insights into NOACs and Reversal
Stroke Prevention and Treatment: New Insights into NOACs and Reversal Received 16 July 2018; Accepted 21 July 2018 A B S T R A C T Non-vitamin-K oral anticoagulants (NOACs) have become the standard of
More informationLaboratory Monitoring Measurement of the DOACs
1 Laboratory Monitoring Measurement of the DOACs ACC Anticoagulation Consortium Roundtable Meeting October 24, 2015 Adam Cuker, MD, MS Perelman School of Medicine University of Pennsylvania 2 Full disclosures
More informationAtrial Fibrillation. 2 nd Annual National Hospitalist Conference San Antonio, TX September 7, 2018
2 nd Annual National Hospitalist Conference San Antonio, TX September 7, 2018, MSc, FACP, SFHM Division of Hospital Medicine Henry Ford Hospital Detroit, USA Clinical Associate Professor of Medicine Wayne
More informationFACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS
New Horizons In Atherothrombosis Treatment 2012 순환기춘계학술대회 FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS Division of Cardiology, Jeonbuk National University Medical School Jei Keon Chae,
More informationParadigm Shift In Oral Anticoagulation Non-Vitamin K Oral Anticoagulants(NOACs) -
Paradigm Shift In Oral Anticoagulation Non-Vitamin K Oral Anticoagulants(NOACs) - Mohammad Taha, MD University of Kansas Medical center, Kansas city, KS Abebe Abebe, MD University of Kansas Medical Center,
More informationDirect Oral Anticoagulant Use in Older Adults Brian Skinner, PharmD
Direct Oral Anticoagulant Use in Older Adults Brian Skinner, PharmD Dr. Skinner serves as an Assistant Professor of Pharmacy Practice at Manchester University, and he is one of three Internal Medicine
More informationDabigatran Evidence in Real Practice
ADVANCES IN CARDIAC ARRHYTHMIAS and GREAT INNOVATIONS IN CARDIOLOGY XXVII GIORNATE CARDIOLOGICHE TORINESI Torino, Centro Congressi Unione Industriale 23-24 Ottobre 2015 Dabigatran Evidence in Real Practice
More informationEdoxaban. Direct Xa inhibitor Direct thrombin inhibitor Direct Xa inhibitor Direct Xa inhibitor
This table provides a summary of the pharmacotherapeutic properties, side effects, drug interactions and other important information on the four anticoagulant medications currently in use or under review
More informationReversal Agents and Peri-procedural Management
Contemporary Approach to Anticoagulation Management Reversal Agents and Peri-procedural Management Alawi A. Alsheikh-Ali, MD, MSc College of Medicine Mohammed Bin Rashid University of Medicine and Health
More informationReversal of Direct Oral Anticoagulants. Why are we now seeing so many patients on DOACs? Objectives. DOAC: Recurrent VTE. DOAC: Intracranial Bleeding
Reversal of Direct Oral Anticoagulants Cameron D Griffiths, MD, FRCPC Clinical Assistant Professor Division of Hematology UBC Objectives Review efficacy and safety data for Direct Oral Anticoagulants (DOACs)
More informationidarucizumab 2.5g/50mL solution for injection/infusion (Praxbind ) SMC No. (1178/16) Boehringer Ingelheim Ltd
idarucizumab 2.5g/50mL solution for injection/infusion (Praxbind ) SMC No. (1178/16) Boehringer Ingelheim Ltd 05 August 2016 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationANTI-THROMBOTIC THERAPY in NON-VALVULAR ATRIAL FIBRILLATION
ANTI-THROMBOTIC THERAPY in NON-VALVULAR ATRIAL FIBRILLATION Colin Edwards Auckland Heart Group Waitemata Health June 2015 PFIZER Lecture series Disclosures EPIDEMIOLOGY Atrial fibrillation is the most
More informationADC Slides for Presentation 02/10/2017
ADC 2017 Slides for Presentation ANTI THROMBOTIC THERAPY FOR NON VALVULAR ATRIAL FIBRILLATION IN PATIENTS WITH CHRONIC KIDNEY DISEASE: CURRENT VIEWS Martin A. Alpert, MD Brent M. Parker Professor of Medicine
More informationDOACs Advances and Limitations in Real World. Lee Lai Heng Haematology Singapore General Hospital
DOACs Advances and Limitations in Real World Lee Lai Heng Haematology Singapore General Hospital Disclosures for In compliance with COI policy, ISTH requires the following disclosures to the session audience:
More information